Clinical Cancer Genomics Gives Bioinformatics Businesses A Boost
This article was originally published in Start Up
New products are combining genomic information with drug and clinical data to help oncologists make better treatment decisions. Buoyed largely by demand in oncology, is the time ripe to build lasting companies on bioinformatics platforms?
You may also be interested in...
Microarray and sequencing specialist Illumina has entered the consumer genomics game with a DTC personal genome sequencing service. It's distancing itself from regulators by partnering with others to handle any secondary data interpretation and dialog with customers, but cautious or not, by reaching out directly to the public, the move does turn on its head the traditional notion of first developing a technology tool for research, then moving on to more regimented clinical applications.
Both providers and users of digital pathology are confident that clinical use cases and the evidence needed to assure payers and encourage investment by commercial labs will overcome challenges around access and adoption.
Pharma companies are applying digital pathology throughout their research and development functions. Where are they now finding value?